FISCHER MEDICAL VENTURES LIMITED
₹24.75-₹1.09 (-4.2%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹2,621 Cr
- EV / EBITDA
- 4662.3x
- Revenue
- ₹5.22 Cr
- Net margin
- 3.5%
- ROCE
- -0.2%
Price chart
Technical chartScreen technicals →-78.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -26.1%
- 3M
- -36.2%
- 6M
- -35.0%
- 1Y
- -78.9%
- 5Y
- +113.9%
52-week range
Day change -₹1.09 (-4.2%) from ₹26 to ₹25 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in FISCHER, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 129.8%
Concerns1
- Low return on equity of 0.5%
Rule-based from financial data. Not advice.
About the company
Fischer Medical Ventures Limited engages in the manufacture, distribution, leasing, and maintenance of medical equipment in India and internationally.
Read moreShow less
Fischer Medical Ventures Limited engages in the manufacture, distribution, leasing, and maintenance of medical equipment in India and internationally. Its product portfolio includes magnetic resonance imaging (MRI) systems; preventive health kiosks; e-health access points; software solutions; cancer, TB screening, and handheld x-ray; spincare technology; nutraceuticals from plant extracts; mental health solutions; contactless screening solutions; and CT scan systems, as well as preventive diagnostic devices and ancillary medical instruments. The company was formerly known as Fischer Chemic Limited and changed its name to Fischer Medical Ventures Limited in March 2024. Fischer Medical Ventures Limited was incorporated in 1993 and is headquartered in Chennai, India.
- Sector
- Healthcare
- Shares outstanding
- 65.4 Cr shares
- ISIN
- INE771F01041
- BSE code
- 524743
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹2,621 Cr
- P/B
- 7.7x
- EV / EBITDA
- 4662.3x
- EV / Sales
- 226.4x
- P/S
- 227.3x
- 52-week high
- ₹117.65
- 52-week low
- ₹23.97
Profitability
- Operating margin
- -1.6%
- Net margin
- 3.5%
- EBITDA margin
- 4.9%
- ROE
- 0.5%
- ROCE
- -0.2%
- ROA
- 0.4%
- Dividend payout
- 0.0%
- Tax rate
- 25.9%
- Other income, % of PBT
- 138.9%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹5.22 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -54.7%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 129.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹56 L
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2700.0%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 65.0%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹8.0 L
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -153.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹28 L
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 26137.1%
Solvency and efficiency
- Current ratio
- 7.56
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- Financial leverage
- 1.15
- CFO / Net profit
- 0.20
- Cash / Market cap
- 1.9%
- Cash per share
- ₹0.77
- Asset turnover
- 0.13
- Fixed asset turnover
- 1153.00
- Capital intensity
- 0.00
- Debtor days
- 402 days
- Cash conversion cycle
- 402 days
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Sales | ₹5 Cr |
| Expenses | ₹7 Cr |
| Operating profit | -₹2 Cr |
| Other income | ₹3 Cr |
| Interest | ₹13 L |
| Depreciation | ₹13 L |
| Profit before tax | ₹96 L |
| Tax and other | ₹30 L |
| Net profit | ₹66 L |
Revenue and net profit
Revenue fell 54.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹17 L | ₹14 L |
| FY2022 | ₹0 Cr | -₹23 L |
| FY2023 | ₹18 L | -₹4.0 L |
| FY2024 | ₹12 Cr | ₹40 L |
| FY2025 | ₹5 Cr | ₹66 L |
Cash flows
FY2025: -₹24.1 Cr from operations, -₹256 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -₹6.0 L | -₹6.0 L |
| FY2022 | -₹18 L | -₹18 L |
| FY2023 | -₹15 L | -₹15 L |
| FY2024 | ₹8.0 L | -₹38 Cr |
| FY2025 | -₹24 Cr | -₹256 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹5 Cr-54.7%1Y
- Net profit
- ₹66 L+65.0%1Y
- Cash from operations
- -₹24 Cr
- Free cash flow
- -₹256 Cr
- Revenue CAGR, 5Y
- 129.8%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹5 Cr | -₹2 Cr | — | ₹66 L | -₹24 Cr | -₹256 Cr | 0.2% | -54.7% | +65.0% |
Monthly returns
Month-by-month returns of FISCHER across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹359 Cr |
| Equity capital | ₹64 Cr |
| Reserves | ₹272 Cr |
| Borrowings | ₹22 Cr |
| Other liabilities | ₹74 L |
| Assets | ₹359 Cr |
| Fixed assets | ₹68 L |
| Capital work in progress | ₹0 Cr |
| Investments | ₹294 Cr |
| Other assets | ₹63 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
FISCHER has no positive P/E; the peer median is 52.6x.
Not shown (no positive earnings and no EV / Sales): FISCHER MEDICAL VENTURES LIMITED, Suven Life Sciences Ltd.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| FISCHER MEDICAL VENTURES LIMITEDFISCHERthis company | ₹2,621 Cr | — | 7.7x | 0.5% | 4662.3x |
| Indraprastha Medical Corporation LtINDRAMEDCO | ₹3,742 Cr | 21.4x | 5.7x | 25.9% | 17.5x |
| Orchid Pharma LimitedORCHPHARMA | ₹3,739 Cr | 51.8x | 2.8x | — | — |
| Suven Life Sciences Ltd.SUVEN | ₹3,490 Cr | — | 3.3x | -0.9% | -1728.5x |
| Medi Assist Healthcare Services LimitedMEDIASSIST | ₹3,312 Cr | 82.7x | 12.0x | 8.8% | 89.0x |
| Gufic BioSciences Ltd.GUFICBIO | ₹3,200 Cr | 58.9x | 5.1x | 16.1% | 22.7x |
| Unichem Laboratories Ltd.UNICHEMLAB | ₹2,905 Cr | 34.6x | 1.2x | -4.0% | 111.4x |
| Hikal Ltd.HIKAL | ₹2,624 Cr | 257.0x | 2.2x | 5.9% | 12.1x |
| Vimta Labs Ltd.VIMTALABS | ₹2,454 Cr | 32.9x | 5.9x | 13.1% | 27.1x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
FISCHER since 1 January, against earlier years.
Historical volatility
FISCHER's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | -11.8% |
| FY2022 | — |
| FY2023 | 11.1% |
| FY2024 | -1.6% |
| FY2025 | -42.9% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹5 Cr |
| Costs | |
| Interest | ₹13 L |
| Expenses | ₹7 Cr |
| Operating profitOperating Profit | -₹2 Cr |
| Other income and charges | |
| Profit before tax | ₹96 L |
| Tax | |
| Net profitNet Profit | ₹66 L |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹359 Cr |
| Equity capitalEquity Capital | ₹64 Cr |
| Reserves | ₹272 Cr |
| Borrowings | ₹22 Cr |
| Other liabilitiesOther Liabilities | ₹74 L |
| AssetsTotal Assets | ₹359 Cr |
| Fixed assetsFixed Assets | ₹68 L |
| Capital work in progressCWIP | ₹0 Cr |
| Investments | ₹294 Cr |
| Other assetsOther Assets | ₹63 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | -₹24 Cr |
| Investing cash flowCash from Investing Activity | -₹232 Cr |
| Financing cash flowCash from Financing Activity | ₹256 Cr |
| Change in cashNet Cash Flow | ₹28 L |
Learn while you research
Academy chapters picked for FISCHER MEDICAL VENTURES LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read